GEP with radiation for recurrent nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a combination of a chemotherapy drug (GEP) and radiation for people whose nasopharyngeal cancer has come back and cannot be treated with standard local treatments like surgery or radiation. The goal is to see if this approach can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your nasopharyngeal cancer has come back (recurrent) and cannot be treated with surgery or radiation to that spot.
- You have at least one tumor that can be measured on a scan.
- Your blood counts, liver, kidney, and heart function are within acceptable ranges.
- You are willing to follow the study schedule and procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
This trial tests a combination of three treatments—a targeted cancer drug (becotatug vedotin), an immunotherapy drug (PD-1 antibody), and radiation therapy—for nasopharyngeal cancer that has come back after initial treatment. The goal is to see if this combination can shrink the tumor and help you live longer.
This trial tests whether giving chemotherapy plus immunotherapy (pembrolizumab) before and after surgery can help people whose nasopharyngeal cancer has come back in the same area (locally recurrent). The goal is to see if this approach improves outcomes.
This trial uses proton therapy (a precise type of radiation) to treat people whose nasopharyngeal cancer has come back. It aims to see if this treatment can help control the cancer while limiting side effects.
This trial tests combining low-dose radiation with an immunotherapy drug (toripalimab) and chemotherapy for people whose nose and throat cancer has come back or spread. The goal is to see if this combination works better than standard treatments.
This trial tests a combination of high and low dose radiation plus an immunotherapy drug (PD-1 inhibitor) for people whose nasopharyngeal cancer has come back after previous treatment. The goal is to see if this approach can be more effective while reducing side effects.
Hear when a new Nasopharynx Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.